´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-09-23±³À°ÀÏÀÚ : 2022-09-23
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü
±³À°ÁÖÁ¦ :
´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ¿ì¿ï.Á¶¿ïº´ÇÐȸ (ÀÌ»çÀåÁ¦)
´ã´çÀÚ : ¿ì¿µ¼·
¿¬¶ôó : 02-3770-1139
À̸ÞÀÏ :
webmaster@thekasad.or.kr ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 13 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í »çÀüµî·Ï: Á¤È¸¿ø 6¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø, ºñȸ¿ø 7¸¸¿ø, Æò»ýȸ¿ø ¸éÁ¦´çÀϵî·Ï: Á¤È¸¿ø 8¸¸¿ø, ÁØȸ¿ø 6¸¸¿ø, ºñȸ¿ø 9¸¸¿ø, Æò»ýȸ¿ø 1¸¸¿ø¤½
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:30~09:50 Mood and personal traits as risk factors for physical illness È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:50~10:10 Inflammation, physical illness, and depression ½Å»óÈ£(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:10~10:40 Metabolic syndrome and bipolar disorder °¿ø¼·(°æÈñÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:55~11:20 Introduction to Research Domain Criteria (RDoC) ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:20~11:45 Utility of Research Domain Criteria (RDoC) for mood disorders research Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:45~12:10 Clinical use of Research Domain Criteria (RDoC) for mood disorders À±¼¿µ(´ë±¸°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:10~12:40 A paradigm shift to recover from depression Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:40~13:10 Therapeutic advantage of Agomelatine in treating depression ¼Á¤¼®(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 13:30~13:50 Is bipolar patients more vulnerable to antipsychotic-induced side effects than schizophrenia patients? ±è°æ¹Î(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 13:50~14:10 Is there a difference in therapeutic effects on somatic symptoms of depression between Selective serotonin reuptake inhibitors (SSRIs) and Serotonin and norepinephrine reuptake inhibitors (SNRIs)? ¼Û¹Î±Ô(¼º¸ð°ø°¨Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:10~14:40 What are the optimal treatment strategies for bipolar disorder in the child-bearing woman? ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:40~15:40 Mindfulness-based interventions for depression ÀÌ°¿í(°¿øÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 15:50~16:10 Neurobiology of psychedelic drugs ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:10~16:30 Therapeutic potentials of psychedelic drugs ¿ÀÈ«¼®(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:30~17:00 Evidence of psychedelic treatment for depression °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 09:30~09:50 Environmental factors ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 09:50~10:10 Genetic factors ¾çÂù¸ð(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 10:10~10:40 Gene-environment Interaction ÀÌ»ó¹Î(°æÈñÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 10:55~11:20 Machine learning based Electroencephalogram (EEG) ±èÁö¼±(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 11:20~11:45 Functional Near Infrared Spectroscopy (fNIRS) ÀÌ¿¬Á¤(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 11:45~12:10 Functional and structural Magnetic Resonance Imaging (MRI) ÇѱԸ¸(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 12:10~12:40 Recent issue and clinical update on treatment of depressive disorders À̹®¼ö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 12:40~13:10 Efficacy of Duloxetine on somatic symptoms and pain in depression ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 13:30~13:50 Dialectical Behavior Therapy (DBT) ±è¿ø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 13:50~14:10 Pharmacotherapy ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 14:10~14:40 Brain stimulation (Transcranial direct current stimulation, Transcranial Magnetic Stimulation, Electroconvulsive therapy) ±è¼±¹Ì(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 14:40~15:10 Importance of multifactorial condition management ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 15:10~15:40 Successful management of patient adherence ½É¼¼ÈÆ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 15:50~16:10 Posttraumatic Stress Disorder (PTSD) and depression after trauma exposure À̺´Ã¶(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 16:10~16:30 Suicidal behaviors associated with Posttraumatic Stress Disorder (PTSD) and depression ÀüÁø¿ë(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 16:30~17:00 Treating depression of victims ±è¿øÇü(ÀÎÇÏÀÇ´ë)